CLOs on the Move

KC Pharmaceuticals

www.kc-ph.com

 
KC Pharmaceuticals is a Pomona, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.kc-ph.com
  • 3201 Producer Way
    Pomona, CA USA 91768
  • Phone: 909.598.9499

Executives

Name Title Contact Details

Similar Companies

Dracen Pharmaceuticals

Dracen is a privately funded biotech company developing drugs in the area in of immuno metabolism.

Quality of Life Health Services

Quality of Life Health Services is a Gadsden, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ILC Dover

At SI Group, we create smart chemistry that solves global challenges and makes great things possible. We create smart chemistry that solves global challenges and makes great things possible. SI Group is a performance additives and intermediates business. We offer a broad array of products that feed into diverse applications including pharmaceuticals; plastics; oil and gas; and tires, among many others. We create solutions that provide formulators and manufacturers with the ability to increase efficacy, efficiency, productivity, and purity in countless industrial and consumer goods. Our company unites us. So do our values and the approach that we bring into the workplace each day.

Edesa Biotech Incorporated

Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing innovative ways to treat inflammatory and immune-related diseases. Our most advanced drug candidate is EB05 (paridiprubart), a monoclonal antibody developed for acute and chronic disease indications that involve dysregulated innate immune responses. Edesa is currently evaluating EB05 in a Phase 3 study as a potential treatment for Acute Respiratory Distress Syndrome (ARDS), a life-threatening form of respiratory failure. In addition, Edesa is developing an sPLA2 inhibitor, EB01, as a topical treatment for chronic Allergic Contact Dermatitis (ACD), a common occupational skin condition. The company has also received regulatory approval to conduct a Phase 2 trial its EB06 monoclonal antibody as a treatment for vitiligo, a life-altering autoimmune disease that causes skin to lose its color in patches. We also are planning a future Phase 2 study of paridiprubart for systemic sclerosis (scleroderma), an autoimmune rheumatic disorder that causes fibrosis (scarring/hardening) of skin and internal organs.

The Dunn Group

The Dunn Group is a Totowa, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.